title: Biologics in the treatment of chronic pain: a new era of therapy?
abstract: Existing analgesics fail to provide adequate pain relief in a significant proportion of patients complaining of chronic pain. Furthermore, their use is limited by tolerability and safety concerns. Thus, there is a huge unmet need for effective and safe innovative painkillers. Considering the major role of nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, the issue is whether anti-NGF biologics under development might offer such an opportunity.
authors: Department of Rheumatology, Pellegrin Hospital Center, University Hospital of Bordeaux, Bordeaux, France; Department of Therapeutics, Division of Health, University of Bordeaux, Bordeaux, France.
authors: B
authors: B
authors: Bannwarth
authors: M
authors: M
authors: Kostine
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D059408:Pain Management / Q000639:trends*
chemical_list: D000911:Antibodies, Monoclonal; D020932:Nerve Growth Factor